Clinical Trials Browser

INDUSTRY × Interventional × aumolertinib × Clear all

NCT07183189 2026-04-14

A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07130916 2025-08-19

A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06417008 2025-08-01

A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04923906 2024-11-25

Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04687241 2024-11-07

Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05493501 2024-05-02

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

Phase 3 Terminated

8 enrolled 7 charts

NSCLC

NCT05430386 2023-02-14

Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC

Phase 1 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02981108 2023-01-23

A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC

Phase 1/2 Unknown

364 enrolled 29 charts

Carcinoma, Non-Small-Cell Lung

NCT03849768 2023-01-20

A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients

Phase 3 Unknown

429 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT05503888 2022-08-17

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

Phase 1/2 Not yet recruiting

Recurrence

NCT04951635 2022-06-16

A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05223595 2022-02-04

A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC

Phase 1 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04951648 2021-07-07

A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung